AbbVie annual depreciation and amortization
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Depreciation & Amortization Growth & History (ABBV)
AbbVie's depreciation and amortization was $8.14B for fiscal 2025.
View full AbbVie company overviewAbbVie annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.14B | −$247.0M | −2.95% |
| 2024 | 2024-12-31 | $8.39B | −$312.0M | −3.59% |
| 2023 | 2023-12-31 | $8.70B | $231.0M | +2.73% |
| 2022 | 2022-12-31 | $8.47B | −$54.0M | −0.63% |
| 2021 | 2021-12-31 | $8.52B | $2.05B | +31.68% |
| 2020 | 2020-12-31 | $6.47B | $4.45B | +220.82% |
| 2019 | 2019-12-31 | $2.02B | $252.0M | +14.28% |
| 2018 | 2018-12-31 | $1.76B | $264.0M | +17.59% |
| 2017 | 2017-12-31 | $1.50B | $312.0M | +26.24% |
| 2016 | 2016-12-31 | $1.19B | $353.0M | +42.22% |
| 2015 | 2015-12-31 | $836.0M | $50.0M | +6.36% |
| 2014 | 2014-12-31 | $786.0M | −$111.0M | −12.37% |
| 2013 | 2013-12-31 | $897.0M | −$253.0M | −22.00% |
| 2012 | 2012-12-31 | $1.15B | −$122.0M | −9.59% |
| 2011 | 2011-12-31 | $1.27B | — | — |
AbbVie quarterly depreciation and amortization
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.89B | −$192.0M | −9.20% |
| Q1 2026 | 2026-03-31 | $1.94B | −$103.0M | −5.05% |
| Q4 2025 | 2025-12-31 | $1.99B | — | — |
| Q3 2025 | 2025-09-30 | $2.09B | $1.0M | +0.05% |
| Q2 2025 | 2025-06-30 | $2.09B | $2.0M | +0.10% |
| Q1 2025 | 2025-03-31 | $2.04B | −$35.0M | −1.69% |
| Q3 2024 | 2024-09-30 | $2.09B | −$105.0M | −4.78% |
| Q2 2024 | 2024-06-30 | $2.08B | −$206.0M | −9.00% |
| Q1 2024 | 2024-03-31 | $2.07B | −$53.0M | −2.49% |
| Q3 2023 · Sep 30 | 2023-09-30 | $2.20B | $15.0M | +0.69% |
| Q2 2023 · Jun 30 | 2023-06-30 | $2.29B | $287.0M | +14.33% |
| Q1 2023 · Mar 31 | 2023-03-31 | $2.13B | $74.0M | +3.60% |
| Q3 2022 · Sep 30 | 2022-09-30 | $2.18B | $58.0M | +2.73% |
| Q2 2022 · Jun 30 | 2022-06-30 | $2.00B | −$198.0M | −9.00% |
| Q1 2022 · Mar 31 | 2022-03-31 | $2.05B | −$162.0M | −7.31% |
| Q3 2021 · Sep 30 | 2021-09-30 | $2.12B | −$152.0M | −6.68% |
| Q2 2021 · Jun 30 | 2021-06-30 | $2.20B | $652.0M | +42.09% |
| Q1 2021 · Mar 31 | 2021-03-31 | $2.21B | $1.66B | +296.24% |
| Q3 2020 · Sep 30 | 2020-09-30 | $2.27B | $1.77B | +352.29% |
| Q2 2020 · Jun 30 | 2020-06-30 | $1.55B | $1.05B | +208.57% |
| Q1 2020 · Mar 31 | 2020-03-31 | $559.0M | $56.0M | +11.13% |
| Q3 2019 · Sep 30 | 2019-09-30 | $503.0M | $68.0M | +15.63% |
| Q2 2019 · Jun 30 | 2019-06-30 | $502.0M | $59.0M | +13.32% |
| Q1 2019 · Mar 31 | 2019-03-31 | $503.0M | $58.0M | +13.03% |
| Q3 2018 · Sep 30 | 2018-09-30 | $435.0M | $56.0M | +14.78% |
| Q2 2018 · Jun 30 | 2018-06-30 | $443.0M | $64.0M | +16.89% |
| Q1 2018 · Mar 31 | 2018-03-31 | $445.0M | $71.0M | +18.98% |
| Q3 2017 · Sep 30 | 2017-09-30 | $379.0M | $75.0M | +24.67% |
| Q2 2017 · Jun 30 | 2017-06-30 | $379.0M | $90.0M | +31.14% |
| Q1 2017 · Mar 31 | 2017-03-31 | $374.0M | $106.0M | +39.55% |
| Q3 2016 · Sep 30 | 2016-09-30 | $304.0M | $77.0M | +33.92% |
| Q2 2016 · Jun 30 | 2016-06-30 | $289.0M | $99.0M | +52.11% |
| Q1 2016 · Mar 31 | 2016-03-31 | $268.0M | $110.0M | +69.62% |
| Q3 2015 · Sep 30 | 2015-09-30 | $227.0M | $35.0M | +18.23% |
| Q2 2015 · Jun 30 | 2015-06-30 | $190.0M | −$12.0M | −5.94% |
| Q1 2015 · Mar 31 | 2015-03-31 | $158.0M | −$41.0M | −20.60% |
| Q3 2014 | 2014-09-30 | $192.0M | −$42.0M | −17.95% |
| Q2 2014 | 2014-06-30 | $202.0M | −$34.0M | −14.41% |
| Q1 2014 | 2014-03-31 | $199.0M | −$28.0M | −12.33% |
| Q3 2013 | 2013-09-30 | $234.0M | $7.0M | +3.08% |
| Q2 2013 | 2013-06-30 | $236.0M | −$59.0M | −20.00% |
| Q1 2013 | 2013-03-31 | $227.0M | −$92.0M | −28.84% |
| Q3 2012 | 2012-09-30 | $227.0M | — | — |
| Q2 2012 | 2012-06-30 | $295.0M | — | — |
| Q1 2012 | 2012-03-31 | $319.0M | — | — |
AbbVie depreciation and amortization trends
Over the last five fiscal years, AbbVie's depreciation and amortization increased from $6.47B to $8.14B, a change of $1.67B. The latest reported quarter, Q2 2026, shows $1.89B.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...